Company Profile

BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development. Injectable collagenase clostridium histolyticum is marketed as XIAFLEX (or Xiapex in Europe). The two marketed indications involving its injectable collagenase are Dupuytren's contracture and Peyronie's disease. The other clinical indications for which its collagenase injection has been tested include keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. The Company is evaluating its options for development of additional indications using collagenase.

Employees

Sector

Biotechnology & Medical Research

More about the company

24-04-23	Endo International plc Emerged from Bankruptcy	CI
24-03-22	Fourth Amended Joint Reorganization Plan Approved for Endo International plc	CI
24-03-18	Fourth Amended Joint Reorganization Plan Filed by Endo International plc	CI
24-02-20	Third Amended Joint Reorganization Plan and Disclosure Statement Filed by Endo International plc	CI
24-01-24	Motion for Exclusivity Period Extension Approved For Endo International plc	CI
24-01-12	Combined Hearing for Disclosure Statement and Plan Approved for Endo International plc	CI
24-01-09	Second Amended Joint Reorganization Plan and Disclosure Statement Filed by Endo International plc	CI
24-01-05	First Amended Reorganization Plan and Disclosure Statement Filed by Endo International plc	CI
23-12-18	Joint Reorganization Plan and Disclosure Statement Filed by Endo International plc	CI
23-11-15	Third Motion for Exclusivity Period Extension Approved For Endo International plc	CI
23-07-31	Second Motion for Exclusivity Period Extension Approved For Endo International plc	CI
23-05-25	Two Affiliate Companies Joined Endo International plc Bankruptcy	CI
23-04-03	First Motion for Exclusivity Period Extension Approved For Endo International plc	CI

20-12-02	BIOSPECIFICS TECHNOLOGIES CORP : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
20-11-19	BioSpecifics Technologies : Endo Announces Expiration of Hart-Scott-Rodino Waiting Period For BioSpecifics Tender Offer	AQ
20-11-18	BioSpecifics Technologies : Endo Announces Expiration Of Hart-Scott-Rodino Waiting Period For BioSpecifics Tender Offer	AQ
20-11-10	BioSpecifics Technologies : Reports Third Quarter 2020 Financial and Operating Results	AQ
20-11-09	BIOSPECIFICS TECHNOLOGIES : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ

Date	Insider	Type	Main position	Quantity	% Market Cap.
12/2/20	Corey Fishman	Issuer sale	Director	8,018	0.1092%
12/2/20	Michael Schamroth	Issuer sale	Director	117,616	1.6013%
12/2/20	Paul A. Gitman	Issuer sale	Director	18,616	0.2535%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOSPECIFICS TECHNOLOGIES CORP.	+0.15%	+0.10%	-	-	650M
WUXI APPTEC CO., LTD.	+4.35%	+19.90%	+60.59%	+95.21%	62.53B
ARGENX SE	+2.83%	-3.48%	+24.97%	+69.33%	52.43B
BIONTECH SE	-0.38%	-2.21%	-18.16%	-7.72%	23.1B
INSMED INCORPORATED	+1.39%	-2.58%	-9.99%	+359.35%	21.4B
WUXI BIOLOGICS (CAYMAN) INC.	+0.40%	+5.29%	+30.11%	-9.63%	21.17B
GENMAB A/S	+0.75%	+1.34%	+32.22%	-25.54%	17.76B
PHARMAESSENTIA CORPORATION	+9.88%	+19.73%	+229.67%	+385.49%	15.47B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+2.08%	-3.28%	+21.67%	+564.59%	14.68B
EXELIXIS, INC.	+0.75%	+1.95%	+50.59%	+178.57%	14.08B
Average	+2.23%	+3.65%	+46.85%	+178.85%	26.96B
Weighted average by Cap.	+2.71%	+4.59%	+42.27%	+136.87%

BioSpecifics Technologies Corp. Stock

Stocks

BSTC

US0909311062

Biotechnology & Medical Research

Latest news : BioSpecifics Technologies Corp.

Press Releases: BioSpecifics Technologies Corp.

Quotes and Performance

Latest insider transactions

Bio Therapeutic Drugs

Company Profile